Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
60 participants
INTERVENTIONAL
2009-05-31
2010-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The aim of the study is to assess that blocking the angiotensin II type 1 receptor reduces systemic levels of oxidative stress markers and adhesion molecules by more than 25% compared to placebo in patients with persistent/permanent atrial fibrillation.
Primary Target Parameter:
The primary target parameter is defined as reduction of systemic levels of oxidative stress markers and adhesion molecules (hsCRP, ICAM, VCAM, MCP-1, vWF, TGFβ1, TNF-α, Interleukin-6, 8isoProstaglandinF2α)
Secondary Target Parameter:
The secondary Target Parameters are defined as number of cerebrovascular events, number of intermediate medical visits for cardiovascular reasons without hospitalisation, number of hospitalisations for cardiovascular reasons and GFR.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
2
Placebo treatment in each patient during the study (9 weeks) using an intraindividual cross-over design
placebo
Placebo-tablet, 1 in the morning for 7 days, 2 tablets (1 in the morning and 1 in the evening) after day 8.
1
Irbesartan treatment in each patient during the study (9 weeks) using an intraindividual cross-over design
irbesartan
Irbesartan-tablet (150 mg) 1 in the morning for 7 days, 2 tablets (1 in the morning and 1 in the evening) after day 8 if no contraindication for up titration (investigator will decide on the basis of creatinin, urea and potassium after taking a blood sample) for 9 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
irbesartan
Irbesartan-tablet (150 mg) 1 in the morning for 7 days, 2 tablets (1 in the morning and 1 in the evening) after day 8 if no contraindication for up titration (investigator will decide on the basis of creatinin, urea and potassium after taking a blood sample) for 9 weeks.
placebo
Placebo-tablet, 1 in the morning for 7 days, 2 tablets (1 in the morning and 1 in the evening) after day 8.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* CHADS2 Score ≥2
* Age ≥18
* Patient informed orally and in writing
* Written informed consent of the patient
* Patients who are anticipated to show sufficient compliance in following the study protocol
* Patients must agree to undergo the 148 days clinical follow-up
* Patients who are mentally and linguistically able to understand the aim of the study and the associated risks and benefits of the treatment. The patients, by providing informed consent, agree to this treatment as stated in the patient informed consent document.
Exclusion Criteria
* Symptomatic bradycardia
* Implanted pacemaker or implanted cardioverter/defibrillator with any antitachycardia algorithm in use
* Cardiac surgery or cardiac catheter ablation within the last 3 months prior to randomisation
* Typical angina pectoris symptoms at rest or during exercise
* Known coronary artery disease with indication for intervention
* Symptomatic peripheral vascular disease
* Left ventricular ejection fraction \<35%
* Myocardial infarction within 6 months prior to randomisation
* Diastolic blood pressure \>110mmHg at rest
* Symptomatic arterial hypotension
* Known renal artery stenosis
* Serum creatinin \>1.8mval/l
* Chronic inflammatory disease
* Acute inflammatory disease (CRP \>20mg/L)
* Relevant hepatic or pulmonary disorders
* Hyperthyreosis manifested clinically and in laboratory
* Known drug intolerance for AT II inhibitors
* Females who are pregnant or breast feeding
* Females of childbearing potential who are not using a scientifically accepted method of contraception
* Participation in a clinical trial within the last 30 days prior to randomisation
* Drug addiction or chronic alcohol abuse
* Cancer or other disease, which inevitably leads to death
* Legal incapacity, or other circumstances which would prevent the patient from understanding the aim, nature or extent of the clinical study, evidence of an uncooperative attitude
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sanofi
INDUSTRY
University of Magdeburg
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University Hospital Magdeburg
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andreas Goette, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital Magdeburg; Div of Cardiology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Magdeburg; Div. of Cardiology
Magdeburg, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Veronika Raetzel
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EUDRACTN: 2007-003262-17
Identifier Type: -
Identifier Source: secondary_id
AG-1-2007
Identifier Type: -
Identifier Source: org_study_id